EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abingdon Health's enterprise value is £12.95 Mil.
Abingdon Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £-1.67 Mil. Therefore, Abingdon Health's EV-to-EBITDA for today is -7.77.
The historical rank and industry rank for Abingdon Health's EV-to-EBITDA or its related term are showing as below:
LSE:ABDX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.88 Med: -4.37 Max: 125.1
Current: -7.77
During the past 6 years, the highest EV-to-EBITDA of Abingdon Health was 125.10. The lowest was -24.88. And the median was -4.37.
LSE:ABDX's EV-to-EBITDA is ranked worse than 100% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.625
vs LSE:ABDX: -7.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Abingdon Health EV-to-EBITDA Historical Data
The historical data trend for Abingdon Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Abingdon Health's EV-to-EBITDA
For the Diagnostics & Research subindustry, Abingdon Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abingdon Health's EV-to-EBITDA falls into.
Abingdon Health's current Enterprise Value is £12.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abingdon Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £-1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (LSE:ABDX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Abingdon Health's PE Ratio for today is calculated as:
Abingdon Health's share price for today is £0.11.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abingdon Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Abingdon Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also produces tests covering areas such as self-test HIV, equine infection, human fertility, etc. Business operating segments includes; Contract Development comprises development work for third parties. Contract Manufacturing comprises contract development and manufacturing activities. Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from Contract Development segment. Geographically it operates and earns revenue from the UK, USA and Canada, Europe and the rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:ABDX has been successfully added to your 